FLUXIL CAPSULE 20 mg

Country: Singapor

Lingwa: Ingliż

Sors: HSA (Health Sciences Authority)

Ingredjent attiv:

FLUOXETINE HCl EQV FLUOXETINE

Disponibbli minn:

ZYFAS PHARMA PTE LTD

Kodiċi ATC:

N06AB03

Dożaġġ:

20 mg

Għamla farmaċewtika:

CAPSULE

Kompożizzjoni:

FLUOXETINE HCl EQV FLUOXETINE 20 mg

Rotta amministrattiva:

ORAL

Tip ta 'preskrizzjoni:

Prescription Only

Manifatturat minn:

Delorbis Pharmaceuticals Ltd

L-istatus ta 'awtorizzazzjoni:

ACTIVE

Data ta 'l-awtorizzazzjoni:

2004-07-31

Fuljett ta 'informazzjoni

FLUXIL
Fluxil capsules 20 mg: 10’s, 14’s, 30’s
ACTIVE INGREDIENT: FLUOXETINE HYDROCHLORIDE
CORRESPONDING TO 20MG FLUOXETINE
INDICATIONS:
Adult - Treatment of major depression.
Children - not recommended
ADMINISTRATION & DOSAGE:
The capsule should be swallowed whole with
water. The recommended dose is one capsule
(20mg) taken in the morning. If no improvement
is observed after several weeks, the dose may be
increased. The maximum dose is 80mg a day.
Doses higher than 20mg a day should be divided
and given in the morning and afternoon. As with
other
antidepressants,
the
full
effect
may
be
delayed until 4 weeks of treatment or longer.
A lower dosage should be considered for the
elderly
and
patients
with
renal
or
hepatic
impairment or on multiple medications.
CONTRA-INDICATIONS:
Hypersensitivity to fluoxetine
Patients
taking
monoamine
oxidase
inhibitor
(MAOI) drugs
WARNINGS & PRECAUTIONS:
Serious reactions may occur if given together with
MAOIs or tricyclics. At least 14 days should pass
between discontinuation of MAOI and initiation
of treatment with fluoxetine. Because of the long
half life of fluoxetine, at least 5 weeks should pass
between
discontinuation
of
fluoxetine
and
initiation with a MAOI.
The possibility of suicide attempt is inherent in
depression, close supervision of high risk patients
is advised.
As
with
any
psychoactive
drug,
impaired
judgement or motor skills may occur, and patients
should
not
drive
or
operate
machinery.
Anaphylactoid events, including bronchospasm,
and angioedema, and progressive systemic events,
sometimes serious (involving skin, kidney, liver or
lung)
have
been
reported.
Use
cautiously
in
patients
who
have
a
history
of
seizures,
mania/hypomania, cardiac disease. As fluoxetine
is metabolized by the liver and excreted by the
kidneys, a lower dosage or alternate day dosing is
recommended for patients with renal or hepatic
impairment.
In
patients
with
diabetes
hypoglycaemia has occurred during treatment with
fluoxetine and hyperglycermia has developed
following discontinuation.

Karatteristiċi tal-prodott

FLUXIL
Fluxil capsules 20 mg: 30’s
ACTIVE INGREDIENT: FLUOXETINE HYDROCHLORIDE CORRESPONDING TO 20MG
FLUOXETINE
INDICATIONS:
Adult
Depression
Fluxil is indicated for the treatment of the symptoms of depressive
illness, with or
without associated anxiety symptoms, especially where sedation is not
required.
Obsessive-compulsive disorder
Bulimia nervosa
Fluxil is indicated for the reduction of binge-eating and purging
activity.
ADMINISTRATION & DOSAGE:
Depression, with or without associated anxiety symptoms
Adults and the elderly: A dose of 20 mg/day is recommended
Obsessive compulsive disorder
Adults
and
the
elderly:
20
mg/day
to
60
mg/day.
A
dose
of
20mg/day
is
recommended as initial dose. Although there may be an increased
potential for side
effects at higher doses, a dose increase may be considered after
several weeks if
there is no response.
Bulimia Nervosa
Adults and the elderly: A dose of 60 mg/day is recommended.
All indications
The recommended dose may be increased or decreased. Doses above 80
mg/day
have not been systematically evaluated.
Children
The use of fluoxetine in children is not recommended, as safety and
efficacy have
not been established.
Hepatic impairment
A lower or less frequent dose (e.g. 20mg every second day) should be
considered in
patients with hepatic impairment, or in patients where concomitant
medication has
the potential for interaction with fluoxetine.
Withdrawal symptoms seen on discontinuation of fluoxetine
Abrupt discontinuation should be avoided. When stopping treatment with
Fluxil the
dose should be gradually reduced over a period of at least one to two
weeks in order
to reduce the risk of withdrawal reactions. If intolerable symptoms
occur following a
decrease in the dose or upon discontinuation of treatment, then
resuming the
previously prescribed dose may be considered. Subsequently, the
physician may
continue decreasing the dose, but at a more gradual rate.
Method of administration
For oral administration, with or without food. When dosing is stopped,
active drug
substanc